Lipigon Pharmaceuticals AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was SEK 0.078 million compared to SEK 0.749 million a year ago. Net loss was SEK 6.84 million compared to SEK 11.43 million a year ago. Basic loss per share from continuing operations was SEK 0.36 compared to SEK 1.17 a year ago. Diluted loss per share from continuing operations was SEK 0.36 compared to SEK 1.17 a year ago.
For the nine months, revenue was SEK 0.352 million compared to SEK 2.72 million a year ago. Net loss was SEK 28.51 million compared to SEK 26.69 million a year ago. Basic loss per share from continuing operations was SEK 2.22 compared to SEK 3.04 a year ago. Diluted loss per share from continuing operations was SEK 2.22 compared to SEK 3.04 a year ago.